Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel

Girolamo Ranieri; Ilaria Marech; Mariangela Porcelli; Francesco Giotta; Gennaro Palmiotti; Giuseppe Laricchia; Vito Fazio; Cosmo Damiano Gadaleta

doi:10.18632/oncotarget.23793

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Case Reports:

Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel

Girolamo Ranieri _, Ilaria Marech, Mariangela Porcelli, Francesco Giotta, Gennaro Palmiotti, Giuseppe Laricchia, Vito Fazio and Cosmo Damiano Gadaleta

PDF | HTML | How to cite

Oncotarget. 2018; 9:8197-8203. https://doi.org/10.18632/oncotarget.23793

Metrics: PDF 1420 views | HTML 5330 views | ?

Abstract

Girolamo Ranieri1, Ilaria Marech1, Mariangela Porcelli1, Francesco Giotta1, Gennaro Palmiotti1, Giuseppe Laricchia1 , Vito Fazio1 and Cosmo Damiano Gadaleta1

1 Interventional and Medical Oncology Unit, National Cancer Research Center, Istituto Tumori Giovanni Paolo II, Viale Orazio Flacco, Bari, Italy

Correspondence to:

Girolamo Ranieri, email:

Keywords: hepatic intra-arterial chemotherapy; nab-paclitaxel; liver metastases; breast cancer

Received: November 06, 2017 Accepted: December 11, 2017 Published: December 31, 2017

Abstract

About half of patients with metastatic breast cancer (mBC) have unresectable liver metastases (LMs) or liver-predominant disease (LPD). Unfortunately systemic chemotherapy has limited tumor response due to LMs are supplied by hepatic artery. Hepatic intra-arterial (HAI) have antitumor activity in pretreated patients with LMs. Here we report the case of a 55-year-old woman affected by BCLPD and heavily pretreated. LMs responded to treatment based on HAI with 5-fluorouracil and nab-paclitaxel systemic chemotherapy, and they completely disappeared on a CT-scan. We conclude that this combination chemotherapy is safe and may be very useful for the treatment of patients with BCLPD. Therefore, this combination should be evaluated in a large study.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23793

Publication Alerts

Case Reports:

Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel

Abstract